Back to Search
Start Over
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
- Source :
- The Lancet Respiratory Medicine; April 2024, Vol. 12 Issue: 4 pe21-e30, 10p
- Publication Year :
- 2024
-
Abstract
- Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 12
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs65876609
- Full Text :
- https://doi.org/10.1016/S2213-2600(24)00027-4